Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Früh

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
JAMA Oncology|April 26, 2019
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung CancerFiamma Berner, David Bomze, Stefan Diem, et al.
Nature Communications|September 30, 2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapyDominic Schmid, Bettina Sobottka, Massimiliano Manzo, et al.
Oncoimmunology|December 3, 2021
Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survivalFiamma Berner, Rebekka Niederer, Jolien J Luimstra, et al.
Science Immunology|September 2, 2022
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockadeFiamma Berner, David Bomze, Christa Lichtensteiger, et al.
JTO Clinical and Research Reports|January 13, 2025
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World StudyLaura Moliner, Núria Zellweger, Sabine Schmid, et al.
The Lancet. Respiratory Medicine|April 15, 2017
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Urania Dafni, Enriqueta Felip, et al.
Med (New York, N.Y.)|January 24, 2023
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitorsNicolas Gonzalo Nuñez, Fiamma Berner, Ekaterina Friebel, et al.
American Journal of Respiratory and Critical Care Medicine|April 16, 2024
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint BlockadeNina Wyss, Fiamma Berner, Vincent Walter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global ConsortiumSarah Waliany, Alissa J Cooper, Stephen V Liu, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
JAMA Oncology|April 26, 2019
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung CancerFiamma Berner, David Bomze, Stefan Diem, et al.
Nature Communications|September 30, 2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapyDominic Schmid, Bettina Sobottka, Massimiliano Manzo, et al.
Oncoimmunology|December 3, 2021
Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survivalFiamma Berner, Rebekka Niederer, Jolien J Luimstra, et al.
Science Immunology|September 2, 2022
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockadeFiamma Berner, David Bomze, Christa Lichtensteiger, et al.
JTO Clinical and Research Reports|January 13, 2025
First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World StudyLaura Moliner, Núria Zellweger, Sabine Schmid, et al.
The Lancet. Respiratory Medicine|April 15, 2017
Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trialRafael Rosell, Urania Dafni, Enriqueta Felip, et al.
Med (New York, N.Y.)|January 24, 2023
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitorsNicolas Gonzalo Nuñez, Fiamma Berner, Ekaterina Friebel, et al.
American Journal of Respiratory and Critical Care Medicine|April 16, 2024
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint BlockadeNina Wyss, Fiamma Berner, Vincent Walter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global ConsortiumSarah Waliany, Alissa J Cooper, Stephen V Liu, et al.
Pageof 10